Log In
BCIQ
Print this Print this
 

bb2121

  Manage Alerts
Collapse Summary General Information
Company bluebird bio Inc.
DescriptionAutologous T cells transduced ex vivo with an anti-BCMA02 CAR lentiviral vector delivering the chimeric antigen receptor (CAR) targeted to human tumor necrosis factor (TNF) receptor superfamily member 17 (BCMA; TNFRSF17; CD269)
Molecular Target Tumor necrosis factor (TNF) receptor superfamily member 17 (BCMA) (TNFRSF17) (CD269)
Mechanism of ActionGene therapy
Therapeutic ModalityCell therapy: Non-stem cell
Latest Stage of DevelopmentPhase I
Standard IndicationMultiple myeloma (MM)
Indication DetailsTreat multiple myeloma (MM); Treat relapsed/refractory multiple myeloma (MM)
Regulatory Designation
PartnerCelgene Corp.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

03/25/2013

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today